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Background: Zalypsis® is a marine compound in phase II clinical trials for multiple myeloma, cervical and endometrial
cancer, and Ewing’s sarcoma. However, the determinants of the response to Zalypsis are not well known. The
identification of biomarkers for Zalypsis activity would also contribute to broaden the spectrum of tumors by
selecting those patients more likely to respond to this therapy.
Methods: Using in vitro drug sensitivity data coupled with a set of molecular data from a panel of sarcoma cell
lines, we developed molecular signatures that predict sensitivity to Zalypsis. We verified these results in culture
and in vivo xenograft studies.
Results: Zalypsis resistance was dependent on the expression levels of PDGFRα or constitutive phosphorylation
of c-Kit, indicating that the activation of tyrosine kinase receptors (TKRs) may determine resistance to Zalypsis. To
validate our observation, we measured the levels of total and active (phosphorylated) forms of the RTKs PDGFRα/β,
c-Kit, and EGFR in a new panel of diverse solid tumor cell lines and found that the IC50 to the drug correlated with RTK
activation in this new panel. We further tested our predictions about Zalypsis determinants for response in vivo in
xenograft models. All cells lines expressing low levels of RTK signaling were sensitive to Zalypsis in vivo, whereas
all cell lines except two with high levels of RTK signaling were resistant to the drug.
Conclusions: RTK activation might provide important signals to overcome the cytotoxicity of Zalypsis and should
be taken into consideration in current and future clinical trials.
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During the past 30 years, medical oncologists have fo-
cused on optimizing the outcome of cancer patients by
developing new antitumoral agents and defining new
prognostic factors as well as integrating more effective
supportive care measures. However, clinical anticancer
strategies indicate that conceptually active therapies
benefit only a small proportion of patients; thus, a large
cohort of patients must be exposed to these antitumoral
treatments to obtain a benefit in only a fraction of them.
Pharmacogenomic studies are aimed at identifying pre-
dictive biomarkers that can help to define subpopulations
of patients who will, or will not, benefit from a particular* Correspondence: acarnero-ibis@us.es
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unless otherwise stated.therapy. These molecular markers of a response to a spe-
cific drug are not exclusive to the so-called “Targeted
Therapies” but also have been identified for widely used
cytotoxic agents. Representative examples include the
relationship between mRNA expression and response
and survival using antifolates [1], beta tubulin III mRNA
levels and response to tubulin-interacting agents [2],
PTEN methylation and resistance to CPT-11 [3], and Ras
oncogenic activation and resistance to EGFR-interacting
agents [4].
Zalypsis® (PM00104) is a marine-derived compound
that has shown cytotoxic activity against various human
tumor cell lines both in vitro and in vivo, including cell
lines resistant to other chemotherapeutic agents [5,6].
Zalypsis is a novel antineoplastic agent currently in phase
II clinical development in endometrial and cervical cancer,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gov/ct2/show/NCT01222767).
Structurally, Zalypsis contains a similar chemical scaf-
fold to trabectedin, differing in an additional appended
ring [7]. It has been shown that the trabectedin chemical
scaffold forms a covalent bond with DNA [8], and the
appended ring has been proposed to directly interact
with the nucleotide excision repair (NER) endonuclease
XPG [9,10]. Trabectedin and Zalypsis exhibit overall
similarities and sequence-specific differences in their
DNA footprint properties [7]. In vitro data suggests that
Zalypsis has DNA-binding properties, induces cell cycle
arrest, and inhibits transcription, eventually leading to
apoptosis [5,11]. Although the precise mechanism of
action of this agent remains mostly unknown, there is
increasing experimental data describing Zalypsis’ antitu-
moral activity [12,13]. The binding to the minor groove
of DNA is the main event in the antitumoral activity of
Zalypsis and results in stabilization of the DNA duplex
[11], mimicking a inter-strand crosslink. Treatment of
cells lines with Zalypsis leads to cell cycle delay in S
phase, activation of the DNA damage checkpoint, and
cell death. Additionally, Schizosaccharomyces pombe cells
containing a RAD51 mutation were found to be extremely
sensitive to Zalypsis, suggesting that the compound in-
duces double-strand breaks (DSBs) [5]. Experiments in
isogenic cell lines have indicated that the cytotoxic effect
of this compound is independent of functional nucleotide
excision repair system properties [7]. However, the DNA
damage repair machinery is essential to overcoming
Zalypsis-induced DNA damage, suggesting that this
damage is mainly due to DSBs [5].
The aim of this study was to identify biomarkers defin-
ing the molecular basis of sensitivity/resistance to Zalypsis
to assist in its clinical development. To this end, we used
a panel of solid tumors, including low-passage cell lines
from untreated sarcoma tumor samples [14]. Using this
panel of low-passage tumor cell lines, we assessed sensitiv-
ity to Zalypsis and other drugs currently used in sarcoma
treatment [15] and found well-defined differences in sensi-
tivity to the drugs tested. We analyzed the relationship be-
tween the IC50 to Zalypsis in the panel of tumor cell lines
and the expression of a large panel of molecular markers,
observing significant relationships between the direct al-
terations of the markers and specific compounds. The
most relevant finding was that the increased signaling
from RTKs determines Zalypsis resistance in vitro and in
xenograft models in vivo.
Methods
Cell lines and culture conditions
The panel was composed of commercial and in-house-
generated cell lines from patients of soft tissue sarcomas.
For the generation of new cell lines, sterile fragmentsfrom resected tumors were minced in culture medium
and then disaggregated by 1–2 h incubation in collage-
nase (100 U/ml) at 37°C. After 24 h, the medium was
changed to F-10 Ham (Gibco) supplemented with 1%
Ultroser G (Biosepra). The cell lines generated were cul-
tured in F-10 Ham supplemented with 1% Ultroser G.
A673 cells were cultured in RPMI (Sigma) and SW872
in Leibovitz L-15 (Sigma). All media were supplemented
with 10% FBS, fungizone, and penicillin/streptomycin.
Once the cells became confluent, adherent cells were re-
moved by trypsin treatment and seeded at 1/2 or 1/3 ra-
tio with medium. Throughout the establishment of these
cell lines, their phenotypic features were followed. Add-
itionally, the cell lines were routinely checked for myco-
plasma contamination (INVIVOGEN). All cell lines used
were established immortal tumor cell lines.
For the newly created human cell lines from resected
tumor tissue, approval from local ethics committee at
Hospital Universitario Virgen del Rocio (Comite etico de
investigacion Hospital Universitario Virgen Del Rocío)
was obtained (PI2012-0085) and informed consent was
obtained from patients.
Cytotoxicity assessment
The compounds were tested using 96-well trays. Cells
growing in a flask were harvested just before becoming
confluent, counted using a hemocytometer, and diluted
with media by adjusting the concentration to the re-
quired number of cells per 0.2 ml (volume for each well).
The cells were then seeded in 96-well trays at a density
between 1,000 and 4,000 cells/well, depending on the
cell size. The cells were allowed to settle down and grow
for 24 hours before adding the drugs, which were
weighed and diluted with DMSO to a concentration of
10 mM. A “mother plate” with serial dilutions was pre-
pared at 200X the final concentration in the culture; 11
different concentrations were tested at 1/3 dilution in
a range from 10 μM to 0.1 nM. When necessary, for
highly sensitive or highly resistant cell lines, a new
mother plate was generated by decreasing or increasing
two more concentrations, as required. The final concen-
tration of DMSO in the tissue culture media did not
exceed 0.5%. The appropriate volume of the compound
solution (usually 2 μl) was added automatically (Beckman
FX 96 tip) to the media to reach the final concentration
for each drug. The medium was removed from the cells
and replaced with 0.2 ml of medium dosed with drug.
Each concentration was assayed in triplicate. Two sets
of control wells were included in each plate, containing
either medium without drug or medium with the same
concentration of DMSO. A third control set was obtained
with the untreated cells just before the addition of the
drugs (seeding control, number of cells starting the cul-
ture). The cells were exposed to the drugs for 96 hours
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fore being fixed with 10% glutaraldehyde. The cells were
washed twice, fixed with crystal violet 0.5% for 30 minutes,
washed extensively, solubilized with 15% acetic acid, and
absorbance measured at 595 nm. The value of cytotoxicity
was given as an IC50 concentration, the concentration a
particular drug needed to inhibit by 50% the proliferation
of a cell line or kill 50% of a cell population.
RT-PCR
Total RNA was collected using the TRI-REAGENT
(Molecular Research Center, Inc.). RT was performed
(Promega) with 1 μg of RNA following the manufac-
turer’s protocol. cDNA (1 μg) was used for PCR, and
the amplified products were analyzed by electrophoresis
on a 1% agarose gel. The PCR primers used and the length
of the amplified product are shown in Additional file 1:
Table S1.
Western blot analysis
Whole-cell extracts were prepared from cells and proc-
essed as previously reported [16]. Briefly, the harvested cells
were washed once in cold phosphate-buffered saline (PBS)
and suspended in 1 ml lysis-buffer (50 mM Tris–HCl
pH 7.5, 1% NP-40, 10% glycerol, 150 mM NaCl, 2 mM,
and Complete protease inhibitor cocktail -Roche-). The
protein content of the lysates was determined by the modi-
fied method of Bradford. Proteins were separated on 7.5%
SDS-PAGE gels, transferred onto Immobilon-P membranes
(Millipore), immunostained, and visualized using the ECL
detection system (Amersham). The expression of different
proteins was determined using the antibodies described
in Additional file 2: Table S2.
Statistical analysis
Univariate Cox models were used to analyze the correl-
ation between the IC50 for the drug and the expression
of each biomarker in the cell line panel. For each drug,
we therefore performed 15 Cox regression analyses, one
for each biomarker. The p-values obtained in the Cox
regression analysis were used to determine the relevance
of the biomarker for predicting the sensitivity to the drug.
In vivo xenograft response to Zalypsis
The experimental research on mice performed in this
work complied with institutional, national, and inter-
national guidelines for the welfare of animals and was
approved by the local ethics committee (Comité Ético
de Experimentación Animal(CEEA)/CEI HU Virgen
Del Rocío/IBIS).
Four to six week-old athymic nu/nu mice (Harlan
Sprague Dawley) were s.c. xenografted into their right
flank with approx. 0.5-1 × 107 cells in 0.2 ml of a mixture
(50:50; v:v) of Matrigel basement membrane matrix(Beckton Dickinson, Franklin Lakes, NJ, USA) and serum-
free medium. When the tumors reached approx. 150 mm3,
the mice were randomly assigned into treatment or
control groups. Zalypsis® was intravenously administered
either in 3 consecutive weekly doses (0.9 mg/kg/day) or in
2 cycles of 5 consecutive daily doses (0.3 mg/kg/day). Con-
trol animals received an equal volume of vehicle. Caliper
measurements of the tumor diameters were performed
twice weekly, and the tumor volumes were calculated ac-
cording to the following formula: (a·b)2/2, where a and b
were the longest and shortest diameters, respectively. The
animals were humanely euthanized, according to Institu-
tional Animal Care and Use Committee of PharmaMar,
Inc. (Cambridge, MA, USA) guidelines, when their tumors
reached 3000 mm3 or if significant toxicity (e.g., severe
body weight reduction) was observed. Differences in
tumor volumes between the treated and control groups
were evaluated using the unpaired t-test. Statistical signifi-
cance was defined as p < 0.05. The statistical analyses were
performed by LabCat v8.0 SP1 (Innovative Programming
Associates, Inc. NJ, USA).
Results
Analysis of expression of biomarkers in the cell line panel
The expression of protein and mRNA levels from differ-
ent genes were analyzed under basal conditions in the
absence of the drug and correlated with the in vitro sen-
sitivity after exposure to Zalypsis, trabectedin, and doxo-
rubicin. The panel included 22 genes involved in tumor
progression, cell adhesion, cell cycle control, and cell sig-
naling: Apaf-1, APC, cdk4, c-Kit, cyclin D1, E-cadherin,
MDM2, MLH-1, MSH-2, p14ARF, p15INK4b, p16INK4a,
p21cip1, p27kip1, p53, p73, p85, PDGFRα, p60src, PTEN,
pAKT, and β-catenin. Fourteen genes were analyzed by
the presence or absence of mRNA, and the remaining
genes were evaluated by the protein level (see Additional
file 1: Table S1, Additional file 2: Table S2 and Additional
file 3: Table S3 for indication). For the statistical analysis,
the presence or absence of RNA of each biomarker in
each cell line was scored as 1 or 0, respectively (see
Additional file 3: Table S3). For proteins, intermediate
values were included when some biological relevance
had been described for different levels. Only 15 bio-
markers showed differences among the different cell
lines and were used for the statistical analyses.
Sensitivity to Zalypsis, trabectedin, and doxorubicin of
low-passaged sarcoma cell lines
The panel of low-passage human sarcoma cell lines was
treated with different concentrations of Zalypsis, trabec-
tedin, and doxorubicin. The values of sensitivity (IC50)
to trabectedin and doxorubicin were determined for
comparison. The IC50 values were calculated as an
average of three independent experiments performed in
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between the most sensitive and most resistant cell lines.
In fact, the median IC50 for doxorubicin was 232 nM
(range 14 to >300), indicating at least a 20-fold difference
in sensitivity in the cell lines from the studied panel. The
cell line panel was highly sensitive to trabectedin, with a
median IC50 of 0.7 nM (range 0.1 to >100, 1000-fold
difference). According to a previous report [14], the
value of 1 nM IC50 is considered as the cut-off to separate
cell lines sensitive or resistant to trabectedin (Table 1).
Similarly, the cell line panel showed a broad range of
responses to Zalypsis, with a median IC50 of 502 nM
(range 0.16 to 4933). It is evident that the panel cell lines
can be divided into two groups according to sensitivity
to Zalypsis, sensitive lines with an IC50 below 1 nM and
resistant lines with an IC50 above 100 nM, establishing
a more than 100-fold difference between the sensitive
and resistant groups. Although liposarcoma-derived cell
lines are highly sensitive to trabectedin and Zalypsis,
there is no tissue pattern for the response, and the sensi-
tivity to Zalypsis did not correlate with that for trabecte-
din (Table 1). Both trabectedin and Zalypsis showed aTable 1 IC50±SD values (nM) of a panel of low-passaged
sarcoma cell lines in response to trabectedin, Zalypsis,
and doxorubicin






CNIO AW LIPOSARCOMA 45 0.7 ± 0.1 0.16 ± 0.02
CNIO AX LIPOSARCOMA 44 0.7 ± 0.3 0.32 ± 0.15
SW872 LIPOSARCOMA >300 0.5 ± 0.1 0.87 ± 0.53
1455 LIPOSARCOMA >300 0.1 ± 0.02 0.34 ± 0.32
CNIO AA LEYOMYOSARCOMA 21.5 0.4 ± 0.1 0.5 ± 0.13
CNIO AY LEYOMYOSARCOMA 44 9 ± 0.3 2580 ± 1785
CNIO AZ FIBROUS TUMOR 14 5 ± 0.3 870 ± 184.5
CNIO BC MPNST >300 >100 664.75 ± 450.5
CNIO BB MPNST 232 >100 1008.35 ± 353
A673 EWING SARCOMA 50 1 ± 0.07 0.42 ± 0.39
CNIO BJ OSTEOSARCOMA >300 2 ± 0.32 103.2 ± 4.38
CNIO BF OSTEOSARCOMA 15 0.3 ± 0.04 501.95 ± 9.83
CNIO BP OSTEOSARCOMA >300 0.3 ± 0.05 0.29 ± 0.10
SAOS-2 OSTEOSARCOMA >300 0.11 ± 0.02 0.94 ± 0.74
CNIO BG MIXOID FIBROSARC 22 0.3 ± 0.02 1200 ± 565.69
CNIO BM HIBERNOMA >300 10 ± 0.9 3473 ± 169.71
CNIO BN FIBROHISTIOCITOMA >300 >100 4750 ± 70.71
CNIO CE RABDOMIOSARC >300 >100 2401 ± 637.81
CNIO BI GIST 50 0.1 ± 0.02 4933 ± 644.88
The data represent the average IC50 ± SD of three experiments performed
independently. In the case of doxorubicin, only the average IC50 is shown.
MPNST: Malignant peripheral nerve sheath tumor. GIST: Gastrointestinal
stromal tumor.pattern of sensitivity that was different from doxorubi-
cin, which suggests no cross-resistance.
To explore trabectedin and Zalypsis sensitivity further,
we analyzed the relevance of each of the molecular
markers for trabectedin and Zalypsis responses. To this
end, we performed univariate Cox regression analyses to
determine the relationship between sensitivity to Zalypsis
(IC50) and the expression pattern of each marker across
the cell line panel. Therefore, we performed 15 Cox re-
gression analyses, one for each marker. We then com-
pared the relevance of each molecular marker to the
sensitivity to trabectedin or Zalypsis and compared with
another 12 drugs previously analyzed [17]. The multiple
comparisons were expressed as a sensitivity homology tree
view (Figure 1), which represents the similarity in the rele-
vance of 15 different molecular markers with regard to
drug responses. According to the 15 markers analyzed,
trabectedin and Zalypsis behave differently because they
fall into different sensitivity homology tree branches. We
can also observe that, although Zalypsis behaves similarly
to oxaliplatin, trabectedin is closer to rapamycin or gemci-
tabine (Figure 1). Our sensitivity homology tree does not
group the drugs by mechanism of action but by the rele-
vance of certain markers to predict sensitivity or resist-
ance, which clearly can be independent of the mechanism
of action of each drug. Furthermore, Zalypsis and tra-
bectedin also showed a different marker homology than
doxorubicin, confirming the lack of cross-resistance in vitro
and in patients previously described and indicating thatFigure 1 Sensitivity homology tree. We performed 15 Cox regression
analyses, one for each marker and compared the relevance of each
molecular marker to the responses to trabectedin, Zalypsis, and 12
other drugs. The multiple comparisons are expressed as a sensitivity
homology tree view, which represent the similarity in the relevance of
15 different molecular markers with regard to a response to the drug.
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solid tumors, especially sarcoma.
Statistical analysis of biomarker expression correlation
with sensitivity to Zalypsis
Next, we used the 15 independent univariate Cox re-
gression analyses to determine the relationship between
sensitivity to trabectedin or Zalypsis (IC50) and the ex-
pression pattern of each biomarker. As expected due to
previous work [14], the p53 status was the main deter-
minant of a trabectedin response in our cell line panel.
However, we also found as secondary determinants
PDGFRα and Cyclin D1, with statistically relevant pre-
dictive values.
We also found that the correlation of high PDGFRα
expression and resistance to Zalypsis was the only rela-
tionship showing a statistically relevant value (p < 0.05)A
B
D
Figure 2 Correlation of markers with trabectedin and Zalypsis cytotoxic
with trabectedin or Zalypsis treatment. The number indicates the correlation c
showing the correlation between individual markers and responses in the log
these correlations. B) Correlation of p53 mutations and the trabectedin IC50 (n
c-Kit and the Zalypsis IC50. D) Expression of PDGFRα and c-Kit proteins across(Figure 2A and B). Cell lines with higher a IC50 for
Zalypsis (AZ, BC, AY, BB, BM, BN, BG, and CE) showed
higher levels of PDGFRα. Furthermore, BF (from osteosar-
coma) and BI (from GIST), also resistant to Zalypsis,
showed low PDGFRα levels but high levels of c-Kit
(Figure 2C). A multivariate Cox regression analysis was
also performed to explore the possibility of combining
several markers to obtain a better predictive signature.
In fact, the combined presence of high levels of c-Kit
increased the statistical significance of the correlation
(Figure 2B). None of the cells exhibited increased levels
of EGFR (data not shown). We confirmed the cellular
data for Zalypsis by comparing the cellular levels of
PDGFRα and c-Kit with the IC50 for Zalypsis in each
cell line (Figure 2C). These data suggest that the activation
of either tyrosine kinase receptor could induce resistance
to Zalypsis.C
ity. A) Statistically relevant (p < 0.005) correlations of molecular markers
oefficient between the marker and the drug. B and C) Statistical graphs
rank test or Student t-test. The p value shows the statistical relevance of
M). M: mutant p53; WT: wild-type p53. C) Correlation of PDGFR/PDGFR +
the cell line panel and correlation with sensitivity (IC50 values) to Zalypsis.
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activation
Our aim was to identify a predictive biomarker that al-
lows the use of Zalypsis in a personalized manner and, if
possible, to broaden the spectrum of tumors that can be
treated with this drug. To validate the signature obtained
in the sarcoma cell lines, we selected 9 new cell lines of
other solid tumor origin, which, different from the low-
passaged sarcoma cell lines, can also grow as xenografts
and therefore can also be used for in vivo validation.
The 9 cell lines were subjected to analysis to deter-
mine the levels of RTKs. To this end, we broadened the
proteins analyzed and examined PDGFRα, PDGFRβ,
EGFR, and c-Kit activation (measured as receptor phos-
phorylation) and the total levels at 10% or 0.5% serum
(Figure 3). We found constitutive activation of the PDGFR
signal, either α or β, in the A2780, Calu6, HGC27, and
SW1990 cell lines and also in MDA-MB-231 cells. Fur-
thermore, EGFR was constitutively activated in SKOV3
cells. None of the 9 cell lines showed c-Kit activation (data
not shown). The IC50 for Zalypsis in the cell lines showed
a rank from 13 nM to 0.6 nM, with SW1990, Calu6,
and SKOV3 cells presenting an IC50 above the average.
Figure 4A shows a comparison of the IC50 for Zalypsis
with the constitutive activation of RTKs. Figure 4B shows
a comparison of the IC50 of the cell lines with activated
RTKs vs non-activated RTKs, with a borderline statistical
significance (p = 0.069). As in the sarcoma cell line panel,Figure 3 Levels of total or phosphorylated PDGFRα/β receptors (A)
lines used for the in vivo experiments. The data show the levels of prothe cell lines with constitutive RTK activation generally
showed a higher IC50 for Zalypsis in vitro (Figure 4).
However, the correlation did not occur in all cell lines
because MDA-MB-231 cells had a low IC50, indicating
that other factors may contribute to Zalypsis sensitivity
in this cell line.
In vivo response to Zalypsis in xenograft models
In vitro studies indicated that high levels of RTK phosphor-
ylation and activation determined resistance to Zalypsis
treatment. With the aim of validating this marker in vivo,
we generated xenografts from the 9 cell lines that can be
xenografted in mice. We used these cells because the
low-passage sarcoma cells used in the predictive panel
do not grow exponentially when xenografted in im-
munosuppressed mice. The xenografts of the different
cell lines were treated with Zalypsis either at 0.3 mg/
kg/day, qdx5x2. or 0.9 mg/kg/day, qdx7x3. A positive
response was considered a reduction higher than 60%
of the tumor burden with respect to the control, un-
treated tumor.
Of the 9 cell line xenografts tested, 5 responded to
treatment with Zalypsis, and 4 did not respond. The
non-responding xenografts comprised CALU6, HGC27,
SW1990, and SKOV-3 cells (Figure 5), all of which, ex-
cept SKOV-3, showed high levels of phosphorylated
PDGFRα/β (Figure 3A) under high (10%) or low (0.5%)
serum conditions, indicating the constitutive expressionor total or phosphorylated EGFR (B) in the nine solid tumor cell
teins measured by western blotting.
Figure 4 Correlation of Zalipsis IC50 with RTK activation. A) Graph showing the mean IC50 values for Zalypsis with respect to the average
values for all IC50s. The bold bars indicate no constitutive activation of RTKs. The hatched bars indicate the activation of RTKs. The number above
the bars shows the average IC50 values (nM) for the nine tumor cell lines. B) Graph comparing in groups the IC50 of cell lines with RTK activated
or not activated. The Student T test was used to explore the statistical relevance.
Figure 5 In vivo response of 9 carcinoma cell lines to Zalypsis treatment. A total of 1 million cells were xenografted in nude mice. Once the
tumors reached 100 mm3, Zalypsis treatment was initiated, as indicated. The tumors were measured weekly. (■, C: solvent-only treated mice)
(▲, Z: Zalypsis-treated mice). Quintuplicate samples were used in each experiment.
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line expressing high levels phosphorylated-EGFR, indi-
cating a constitutively active EGF receptor (Figure 3B).
A2780 and MDA-MB-231 cells, with increased levels of
PDGFRα/β, still responded to Zalypsis treatment. The
reason for this specific behavior for these cell lines is
presently unclear and deserves further attention.
Discussion
Compelling evidence from a number of laboratories has
demonstrated the value of using biomarkers to select in-
dividual patients for targeted and non-targeted therapies
[18,19]. The goal is to predict a response to chemother-
apy to use agents in those patients more likely to re-
spond, avoiding unnecessary toxicity. However, in most
cases, the predictors are based on molecular signatures
with low functional value per se. We developed a molecu-
lar signature based on the selection of molecular markers
with functional relevance. The signatures obtained not
only allow for a prediction of a response but also suggest
possible mechanisms to overcoming resistance.
Zalypsis showed a different sensitivity profile from tra-
bectedin in the cell line panel studied, indicating that al-
ternative activities in cellular pathways or specific trends
of intracellular metabolism might determine different ac-
tivities. However, both marine compounds show effective
results in liposarcoma- and fibrohistocytoma-derived cell
lines, two types of cells very resistant to treatment in-
cluding doxorubicin. In the remaining cases, the activity
appears to be more dependent on the cell line than the
tissue type. It is possible that one of the activities of these
compounds is dependent on specific factors present in
some sarcoma types. These specific factors may be the
specific translocations that define certain sarcoma types;
alternatively, the cell lineage-dependent genetic content
may establish the sensitivity or resistance to a specific
drug activity.
Furthermore, we also found that combinations of
PDGFRα/β with other membrane receptors, such as
EGFR or c-Kit, increase the predictability of the re-
sponse to Zalypsis both in vivo and in vitro. RTK consti-
tutive signaling might trigger the constitutive activation
of the survival pathway through MEK or AKT activation,
therefore accounting for the combined effect observed in
our cell line panel both in vivo and in vitro. Active RTKs
activate PI3K, leading to PDK1 and AKT activation [20].
Activated AKT can phosphorylate the pro-apoptotic Bcl-2
family member Bax at S184, inhibiting its conformational
change and its subsequent translocation to mitochondria,
thus preventing Bif-1 binding to Bax and alterations in
mitochondrial membrane potential, cytochrome c release,
caspase activation, and apoptosis [21-24]. Furthermore,
Bcl-XL levels can be regulated by the PI3K pathway;
upregulation of this protein implies survival, whereasdownregulation leads to apoptosis. AKT also phosphor-
ylates Foxo3a, inducing its mislocalization out of the
nucleus and therefore inhibiting its proapoptotic activity
[25]. Similarly, the phosphorylation of MDM2 by AKT in-
duces its binding to p53 and the initiation of degradation,
also acting on cellular survival [26]. However, RTK also
activates the Ras pathway, leading to MEK and ERK acti-
vation, which also phosphorylates Bax to trigger a similar
antiapoptotic response [27]. Additionally, as in the PI3K/
AKT pathway, the Ras pathway can regulate the apoptotic
response through IKK phosphorylation and the regulation
of NFKB signaling [28].
RTK activation has been commonly linked to the re-
sistance to anticancer therapies, either cytotoxic or tar-
geted. Clearly, the upregulation of another receptor or
its ligand, such as MET or HGF in lung cancer resistant
to EGFR inhibitors, is a matter of concern in acquired
resistance to RTK-targeted therapies [29-31]. Furthermore,
TKR activation also has an important role in overcoming
cytotoxicity to chemotherapy in different tumor types. For
example, insulin-like growth factor-I receptor activation
blocks doxorubicin cytotoxicity in sarcoma cells [32], and
the EGFR inhibitor gefitinib sensitizes colon cancer cells
to irinotecan [33]. Cisplatin-resistant neuroblastoma cells
express enhanced levels of epidermal growth factor re-
ceptor (EGFR) and are sensitive to treatment with
EGFR-specific inhibitors [34]. Other receptors such as
TrkB protect neuroblastoma cells from chemotherapy-
induced apoptosis via the phosphatidylinositol 3′-kinase
pathway [35]. RTK inhibition is also effective in chemo-
sensitizing human ovarian, nasopharyngeal, bladder, and
neuroblastoma cancer cell lines, among others, when used
in combination with cytotoxic agents [36-39]. Recently,
we have also reported that SNPs in the PDGFRβ gene
are related to increased levels of receptor and signaling,
promoting chemotherapy resistance in colorectal cancer
patients [40].
The logical conclusion is that the combination of Zalypsis
with tyrosine kinase inhibitors would lead to a greater effi-
cacy of treatment. Because the constitutive activation of
c-Kit might also contribute to resistance, Zalypsis + ima-
tinib may also be an interesting combination. There are
several tyrosine kinase inhibitors approved with different
specificities for different tyrosine kinases [41]. Imatinib and
sunitinib also inhibit PDGFRα and c-Kit and other RTKs,
such as VEGFR1 and FLT3, whereas sorafenib appears to
be more specific for PDGFRβ but also inhibits c-Kit, FLT3,
and VEGFR2. Nilotinib inhibits PDGFRα and -β and c-Kit.
In contrast, gefitinib, erlotinib, and lapatinib are more spe-
cific for the EGFR family. We propose the use of a specific
tyrosine kinase inhibitor according to the RTK active in the
patient’s tumor, thus promoting personalized treatment.
However, further studies have to be conducted to fully
validate this approach.
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We identified a molecular signature based on the com-
bined activation of tyrosine kinase receptors that predicts
resistance to Zalypsis in a broad panel of solid tumor cell
lines. This signature was validated in vivo in xenograft as-
says. This signature deserves validation in tumor samples
of patients treated with Zalypsis, with clinical trials cur-
rently ongoing, and also suggests a potential benefit for
the combination of Zalypsis with tyrosine kinase inhibi-
tors, which warrants further studies.
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